The Zhengye Biotechnology Holding Limited (ZYBT) SEC filings page provides access to the company’s U.S. regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Zhengye Biotechnology files registration and periodic reports with the U.S. Securities and Exchange Commission in connection with its veterinary vaccine business, which focuses on research, development, manufacturing, and sales of vaccines for livestock and other animals.
Key documents for ZYBT include its registration statement on Form F-1, which supported the company’s initial public offering of ordinary shares, and its annual report on Form 20-F, which contains audited financial statements, risk factors, and detailed information about its veterinary vaccine operations in China and abroad. The company also furnishes Form 6-K reports, such as unaudited interim financial statements and management’s discussion and analysis for periods like the six months ended June 30, 2025.
Through this page, users can review how Zhengye Biotechnology reports revenue from swine, poultry, and other vaccines, as well as disclosures on operating expenses, R&D spending, and balance sheet items. Filings may also describe regulatory developments, including Category I New Veterinary Drug approvals granted by the Ministry of Agriculture and Rural Affairs for jointly developed vaccines, and provide context on the company’s geographic reach across China and exports to Vietnam, Pakistan, and Egypt.
Stock Titan enhances these filings with AI-powered summaries that explain complex sections in plain language, highlight key changes from prior periods, and surface notable items such as liquidity trends or customer concentration. Users can quickly scan annual Form 20-F reports, interim Form 6-K updates, and offering-related documents without reading every page, while still having direct access to the full text from EDGAR for deeper analysis.
Zhengye Biotechnology Holding Limited reports that Nasdaq has determined it regained compliance with the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2). This followed 10 consecutive business days, from July 20 to August 4, 2026, during which its Class A ordinary shares closed at or above $1.00. The company remains listed on The Nasdaq Capital Market under the ticker ZYBT.
Zhengye, through its operating entity in Jilin, China, focuses on research, development, manufacturing, and sales of veterinary vaccines. The operating entity offers 50 vaccines for multiple animal species, sells across 29 provincial regions in China, and exports to Vietnam, Pakistan, and Egypt.
Zhengye Biotechnology Holding Limited reports recent unusual price and volume movements in its Class A ordinary shares and states it is not aware of any material non-public information about its business, financial condition, or operations that would explain this trading activity. Management indicates operations continue in the ordinary course and that there have been no undisclosed corporate developments or transactions that would account for the volatility.
The company has contacted Nasdaq about the trading and will cooperate with Nasdaq and other regulators as appropriate. It cautions shareholders and prospective investors to exercise care when evaluating its securities and to rely on information in its U.S. Securities and Exchange Commission filings. Zhengye also describes its veterinary vaccine business in China and selected overseas markets.
Zhengye Biotechnology Holding Ltd director and major shareholder Han Zhenfa has filed an initial Form 3 reporting indirect holdings of the company’s ordinary shares. The filing lists 40,000,000 ordinary shares held by Securingium Holding Limited, 2,278,752 shares held by Vanguards Skyline Holdings Limited, and 684,996 shares held by VVAX Holdings Limited.
These entities are BVI and Chinese holding vehicles that are owned or controlled through structures in which Han is the settlor, beneficiary, protector, or managing partner, reflecting his status as a more than 10% beneficial owner.
Zhengye Biotechnology Holding Ltd filed an initial insider ownership report for Vice General Manager Cheng Yuhong on Form 3. This filing identifies Cheng as an officer of the company but shows no reported transactions, no derivative positions, and no current holdings entries at the time of this statement.
Zhengye Biotechnology Holding Ltd filed a Form 3 for Co-Chief Executive Officer Song Songlin, serving as an initial statement of beneficial ownership. The filing shows no reportable transactions or derivative positions and does not list any buy, sell, acquisition, or disposition activity.
Zhengye Biotechnology Holding Ltd filed an initial Form 3 for Chief Financial Officer Wang Ping. This filing establishes Wang Ping as a reporting insider of ZYBT. It does not list any buy, sell, or derivative transactions, and no holdings details appear in the provided data.
Zhengye Biotechnology Holding Ltd director Jiang Ping (PiJi) filed an initial Form 3 ownership report for ticker ZYBT. The filing lists Jiang Ping as a director but not a ten percent owner, and shows no reported purchases, sales, or other transactions in the company’s securities.
Zhengye Biotechnology Holding Limited reported that Nasdaq has notified the company it is not in compliance with the exchange’s minimum bid price rule. The closing bid for its Class A ordinary shares stayed below $1.00 for 30 consecutive business days through May 28, 2026.
The shares remain listed and continue trading on the Nasdaq Capital Market under the symbol ZYBT. Zhengye has 180 calendar days, until November 25, 2026, for its shares to close at or above $1.00 for at least 10 consecutive business days to regain compliance.
If the company cannot meet this requirement by that date, it may receive an additional 180-day grace period if it satisfies other listing standards and formally outlines a plan to cure the deficiency, potentially including a reverse share split. The company states its business operations are not affected by the notice.
Zhengye Biotechnology Holding Limited, a Cayman Islands holding company, files its annual Form 20‑F covering the year ended December 31, 2025. It reports 47,391,376 ordinary shares outstanding as of December 31, 2025, each with a par value of $0.000025. Subsequent to year‑end, these ordinary shares were reclassified into Class A and Class B Ordinary Shares, creating a dual‑class structure with different voting rights.
The company explains that investors hold equity in the Cayman parent, which indirectly owns PRC and Hong Kong operating subsidiaries. It highlights extensive legal and operational risks from doing business in China, including evolving cybersecurity and data‑security oversight, anti‑monopoly review, and new CSRC overseas listing filing rules. Management notes completion of a CSRC overseas listing filing and states that, based on PRC legal advice, current operations do not trigger cybersecurity review thresholds, though future regulatory changes could affect operations or the value of Class A Ordinary Shares.
The filing also discusses HFCAA and related U.S. laws that could lead to trading prohibitions if the PCAOB cannot fully inspect the company’s auditor, cross‑border cash transfer and dividend restrictions under PRC foreign‑exchange rules, and potential PRC tax residency and withholding tax consequences. Financial statements are prepared in Renminbi and translated at an exchange rate of RMB6.9931 to US$1.00, with the company warning that currency fluctuations may materially affect results and the value of U.S.‑traded shares.
Zhengye Biotechnology Holding Ltd director Hu Qiyi has filed an initial Form 3, which is the required statement of beneficial ownership for insiders. The provided data shows no reported transactions or derivative positions, indicating this filing is purely administrative and does not reflect any recent trading activity.